Comparative study of CNR1 and CNR2 cannabinoid receptors expression levels in COVID-19 patients with and without diabetes mellitus: Recommendations for future research targets.
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
25
03
2022
revised:
28
04
2022
accepted:
05
05
2022
pubmed:
18
5
2022
medline:
15
6
2022
entrez:
17
5
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has prompted researchers to look for effective therapeutic targets. The effect of endocannabinoid system against infectious diseases is investigated for several years. In this study, we evaluated the expression level of CNR1 and CNR2 genes in patients with COVID-19 with and without diabetes to provide new insights regarding these receptors and their potential effect in COVID-19 disease. In this study, peripheral blood monocytes cells (PBMCs) were isolated from eight different groups including COVID-19 patients, diabetic patients, and healthy individuals. RNA were extracted to evaluate the expression level of CNR1 and CNR2 genes using real-time PCR. The correlation between the expression levels of these genes in different groups were assessed. A total of 80 samples were divided into 8 groups, with each group consisting of ten samples. When comparing severe and moderate COVID-19 groups to healthy control group, the expression levels of the CNR1 and CNR2 genes were significantly higher in the severe and moderate COVID-19 groups. There were no significant differences between the mild COVID-19 group and the healthy control group. It was found that the expression levels of these genes in patients with diabetes who were infected with SARS-COV-2 did not differ across COVID-19 groups with varying severity, but they were significantly higher when compared to healthy controls. Our study suggests the possible role of endocannabinoid system during SARS-COV-2 pathogenicity as the expression of CNR1 and CNR2 were elevated during the disease.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The COVID-19 pandemic has prompted researchers to look for effective therapeutic targets. The effect of endocannabinoid system against infectious diseases is investigated for several years. In this study, we evaluated the expression level of CNR1 and CNR2 genes in patients with COVID-19 with and without diabetes to provide new insights regarding these receptors and their potential effect in COVID-19 disease.
METHODS
METHODS
In this study, peripheral blood monocytes cells (PBMCs) were isolated from eight different groups including COVID-19 patients, diabetic patients, and healthy individuals. RNA were extracted to evaluate the expression level of CNR1 and CNR2 genes using real-time PCR. The correlation between the expression levels of these genes in different groups were assessed.
RESULTS
RESULTS
A total of 80 samples were divided into 8 groups, with each group consisting of ten samples. When comparing severe and moderate COVID-19 groups to healthy control group, the expression levels of the CNR1 and CNR2 genes were significantly higher in the severe and moderate COVID-19 groups. There were no significant differences between the mild COVID-19 group and the healthy control group. It was found that the expression levels of these genes in patients with diabetes who were infected with SARS-COV-2 did not differ across COVID-19 groups with varying severity, but they were significantly higher when compared to healthy controls.
CONCLUSION
CONCLUSIONS
Our study suggests the possible role of endocannabinoid system during SARS-COV-2 pathogenicity as the expression of CNR1 and CNR2 were elevated during the disease.
Identifiants
pubmed: 35580523
pii: S1871-4021(22)00113-8
doi: 10.1016/j.dsx.2022.102499
pmc: PMC9078453
pii:
doi:
Substances chimiques
CNR1 protein, human
0
CNR2 protein, human
0
Endocannabinoids
0
Receptor, Cannabinoid, CB1
0
Receptor, Cannabinoid, CB2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102499Informations de copyright
Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest No Conflict of interest.
Références
Nat Prod Rep. 2016 Nov 23;33(12):1357-1392
pubmed: 27722705
J Nat Prod. 2022 Jan 28;85(1):176-184
pubmed: 35007072
Med Cannabis Cannabinoids. 2020 Aug 19;3(2):111-115
pubmed: 34671712
Virulence. 2018 Jan 1;9(1):217-230
pubmed: 28992427
Br J Pharmacol. 2016 Apr;173(7):1116-27
pubmed: 26076890
Drug Discov Today. 2021 Jul;26(7):1750-1758
pubmed: 33781949
Handb Exp Pharmacol. 2005;(168):1-51
pubmed: 16596770
J Neuroinflammation. 2011 Aug 18;8:102
pubmed: 21851608
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190
Viral Immunol. 2018 May;31(4):292-298
pubmed: 29461930
Mol Cell Neurosci. 2014 Mar;59:10-23
pubmed: 24418364
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822
pubmed: 32798472
Aging Clin Exp Res. 2020 Aug;32(8):1599-1608
pubmed: 32557332
Immunobiology. 2010 Aug;215(8):598-605
pubmed: 19457575
Mol Cell Neurosci. 2000 Jun;15(6):510-21
pubmed: 10860578
Future Sci OA. 2020 Aug 13;6(8):FSO625
pubmed: 32974048
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
Int J Biol Sci. 2022 Jan 1;18(2):459-472
pubmed: 35002503
Endokrynol Pol. 2018;69(6):705-719
pubmed: 30618031
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Neuroimmunomodulation. 2017;24(4-5):183-199
pubmed: 29151103
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Cell Metab. 2013 Apr 2;17(4):475-90
pubmed: 23562074
Arch Virol. 2021 Nov;166(11):3117-3126
pubmed: 34514519
Drug Metab Rev. 2021 Nov;53(4):478-490
pubmed: 33683968
Ageing Res Rev. 2021 Jan;65:101205
pubmed: 33137510
Drug Discov Today. 2019 Sep;24(9):1845-1853
pubmed: 31158514